이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

MRI 표적 전립선 생검을 통한 통합 게놈 전립선 점수

2026년 11월 6일 업데이트: National Cancer Institute (NCI)

MRI 표적 전립선 생검과 게놈 전립선 점수 통합에 대한 UAB-NCI 공동 연구

Background:

Prostate cancer is one of the most common cancers in men. For some men, their cancer is monitored. Others have surgery to remove the prostate. Focal therapy is another treatment option. It treats the areas of cancer selectively, which leaves the rest of the prostate intact. This can help lessen side effects. Men who get focal therapy must be chosen carefully. The Oncotype DX Genomic Prostate Score (GPS) assay tests biopsy samples for certain cancer-related genes. It then then gives a score from 1 to 100 to predict the likelihood of poor outcomes. The GPS is used to choose men for focal therapy. Researchers want to test the GPS further.

Objective:

To assess how GPS may be useful when used with MRI to improve how men are chosen for focal therapy of prostate cancer.

Eligibility:

Men age 18 and older who had NCCN low or intermediate risk prostate cancer and had MRI and radical prostatectomy at the Urologic Oncology Branch, National Cancer Institute and collaborating centers.

Design:

This is a multisite study. It will review data and samples that were collected in the past. Samples and images from up to 277 participants will be used.

Tumor tissue will be tested with the GPS.

Data such as age at diagnosis, race, biopsy results, and pathology results will be merged with the GPS results.

Data will be entered into an in-house electronic system. It will be password protected. All data will be kept in secure sites that comply with NIH security standards....

연구 개요

상태

모집하지 않고 적극적으로

정황

상세 설명

Background:

  • Prostate cancer is one of the most common malignancies occurring in men. While many men will qualify for active surveillance (AS), those with intermediate risk disease are often recommended definitive therapy despite the morbidity.
  • Focal therapy for prostate cancer has been promoted as an alternative to the standard paradigm of immediate radical prostatectomy (RP) versus AS for prostate cancer management. Focal therapy treats the areas of cancer selectively, leaving the remainder of the prostate intact.
  • While focal therapy offers great promise in terms of minimizing side effects and helping prostate cancer patients avoid radical therapies, careful patient selection is required.
  • The Oncotype DX Genomic Prostate Score (GPS) assay was developed using the ability to extract and amplify RNA of sufficient quantity and quality from the very small amounts of prostate tumor tissue from biopsy samples. Using these samples, a discovery study identified 12 cancerrelated genes associated with multiple clinically relevant endpoints including adverse pathology, biochemical recurrence, clinical recurrence, and prostate cancer associated death.
  • The GPS assay uses these 12 genes and 5 reference genes to construct an algorithm giving a score from 0-100 to predict the likelihood of adverse pathology.
  • The goal of this study is to evaluate how GPS may be useful in conjunction with MRI to improve patient selection for focal therapy of prostate cancer.

Objectives:

-To determine if there is a positive association between continuous GPS score and occult high risk and/or non-organ confined disease on whole mount prostatectomy specimens where an MRI was performed less than 6 months before diagnostic biopsy, and the biopsy was less than 6 months before RP and the lesion was not identified on multiparameter MRI (mpMRI)

Eligibility:

  • Samples and images from men, over 18 years old, who were diagnosed with NCCN low or intermediate risk prostate cancer and were managed with radical prostatectomy at the Urologic Oncology Branch, National Cancer Institute and collaborating centers
  • Biopsy Gleason Score <= 7
  • Multiparametric MRI, with images available for review, within 6 months prior to the prostatectomy
  • Availability of adequate diagnostic biopsy tissue specimen for GPS analysis

Design:

  • This multisite study will be a prospective analysis of retrospective data.
  • Samples and images will be obtained from will consist of approximately 277 evaluable patients who were diagnosed with NCCN low or intermediate risk prostate cancer and were managed with RP at the Urologic Oncology Branch, National Cancer Institute and collaborating centers.
  • In the interest of a demographically diverse cohort, samples and images from patients from UAB will be identified, working in reverse chronological order until the cohort is complete or eligible specimens are exhausted; remaining cases will then be selected from the NCI patient population, also working in reverse chronological order.
  • Tumor tissue from the highest-grade lesion will be tested with the Oncotype DX Genomic Prostate Scor for generation of the GPS.
  • Clinical characteristics including but not limited to age at diagnosis, race, PSA, biopsy results, Prostate MRI PIRADS score, and surgical pathology results will be collected and merged with GPS results.

연구 유형

관찰

등록 (실제)

241

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Alabama
      • Birmingham, Alabama, 미국, 35294
        • University of Alabama at Birmingham
    • Maryland
      • Bethesda, Maryland, 미국, 20892
        • National Cancer Institute (NCI)

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

남성

샘플링 방법

비확률 샘플

연구 인구

Samples from male patients with NCCN low or intermediate risk disease managed with radical prostatectomy (multiparametric MRI (mpMRI) performed within 6 months prior to the prostatectomy indicating localized, organ confined disease and adequate diagnostic biopsy tissue specimen).

설명

  • INCLUSION CRITERIA:
  • Samples and images from men > =18 with NCCN very low, low, or intermediate risk prostate cancer with tumor tissue that meet the pathologic tissue requirements of the Oncotype DX Genomic Prostate Score assay
  • Biopsy Gleason Score 7 or lower within 6 months preceding radical prostatectomy
  • 3Tesla MRI with/without coil performed within 6 months preceding diagnostic biopsy
  • Availability of diagnostic biopsy

EXCLUSION CRITERIA:

  • Any active therapy received for prostate cancer (e.g., hormonal treatment, radiation, chemotherapy, biologic agents, surgery) prior to radical prostatectomy. 5 alpha reductase inhibitor treatment will not be considered to be hormonal treatment for this definition
  • Men with NCCN high risk or very high-risk prostate cancer
  • Biopsy Gleason 8
  • No biopsy tissue available
  • Missing surgical pathology whole mount, or unwilling to send surgical pathology whole mount to NCI for review
  • Missing diagnostic PSA
  • Missing clinical T stage
  • Known lymph node positive or metastatic disease at time of diagnosis
  • Missing MRI 6 months before diagnostic biopsy

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: RETROSPECTIVE

코호트 및 개입

그룹/코호트
GPS Cohort 1

Samples and images from up to 277 evaluable patients diagnosed with NCCN low or intermediate risk prostate cancer, Gleason <= 7, managed with RP, and mpMRI within 6 months prior to prostatectomy

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
relationship between continuous GPS score and occult high-risk disease
기간: 2-3 years

To determine if there is a positive relationship between continuous GPS score and occult high-risk disease on whole mount prostatectomy specimens where an MRI was performed less than 6 months before diagnostic biopsy, and the biopsy was less than 6 months before RP and the lesion was not identified on mpMRI

2-3 years

2차 결과 측정

결과 측정
측정값 설명
기간
distributions of clinical, pathological and demographic variables
기간: 2-3 years

To compare the distributions of clinical, pathological and demographic variables for the Genomic Health, Inc. (GHI) study cohort with all the eligible samples from patients in the participating institutions databases

2-3 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Peter A Pinto, M.D., National Cancer Institute (NCI)

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2020년 9월 2일

기본 완료 (추정된)

2027년 7월 1일

연구 완료 (추정된)

2027년 7월 1일

연구 등록 날짜

최초 제출

2020년 9월 5일

QC 기준을 충족하는 최초 제출

2020년 9월 5일

처음 게시됨 (실제)

2020년 9월 9일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 9일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 6일

마지막으로 확인됨

2026년 3월 19일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 999920136
  • 20-C-N136

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .